Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …

Azacitidine and decitabine are cytosine analogs that function as DNA methyltransferase
inhibitors. These agents, commonly referred to as “hypomethylating agents,” are widely used …

While it is logical to use hypomethylating agents to treat patients with myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and …

DNA methyltransferase (DNMT) inhibitors, azacitidine (Vidaza®, Pharmion, Boulder, CO,
USA) and decitabine (Dacogen™; SuperGen Inc, Dublin, CA, USA, and MGI Pharma Inc …

The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …

Background Aberrant DNA methylation has been identified as a key molecular event
regulating the pathogenesis of myelodysplastic syndromes (MDS); myeloid neoplasms with …

Azacitidine and decitabine are hypomethylating agents that have dose‐dependent
epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic …

Simple Summary The hypomethylating agents (HMA) azacitidine and decitabine are among
the standard treatment options for myeloid neoplasms. However, the treatment of patients …

Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

Introduction: DNA methylation is an epigenetic change mediated by DNA methyltranferases
(DNMTs), which are promising epigenetic targets for the treatment of acute myeloid …